These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35200071)
1. Geraniin as a potential inhibitor of SARS-CoV-2 3CL Yu WD; Jin QY; Zeng MS; Liu JY; Xu PP Nat Prod Res; 2022 Dec; 36(23):6060-6063. PubMed ID: 35200071 [TBL] [Abstract][Full Text] [Related]
2. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related]
3. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603 [TBL] [Abstract][Full Text] [Related]
4. Binding and inhibitory effect of ravidasvir on 3CL Bera K J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639 [TBL] [Abstract][Full Text] [Related]
5. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. Ahmad B; Batool M; Ain QU; Kim MS; Choi S Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033 [TBL] [Abstract][Full Text] [Related]
7. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070 [TBL] [Abstract][Full Text] [Related]
8. Targeting allosteric pockets of SARS-CoV-2 main protease M Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biochemical Evaluation of 8 Wu J; Feng B; Gao LX; Zhang C; Li J; Xiang DJ; Zang Y; Wang WL Molecules; 2022 May; 27(10):. PubMed ID: 35630836 [TBL] [Abstract][Full Text] [Related]
10. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652 [TBL] [Abstract][Full Text] [Related]
11. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715 [TBL] [Abstract][Full Text] [Related]
13. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation. Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618 [TBL] [Abstract][Full Text] [Related]
15. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292 [TBL] [Abstract][Full Text] [Related]